Objective: The combination of 32 mg naltrexone and 360 mg bupropion prolonged release (NB32) was recently approved by both the food and drug administration (FDA) and the European medicines agency (EMA) as an adjunct to a comprehensive lifestyle intervention to achieve weight loss.
Design: Randomized controlled trials with naltrexone/bupropion prolonged release were selected through a search based on PubMed listings using the terms "bupropion AND naltrexone".
Results: NB32 treatment resulted in 5.0-9.3% weight loss, while the placebo-subtracted weight loss was 3.2-5.2% during 56 weeks of treatment. The proportion of treated patients with ≥ 5% weight loss was 45-66%, while the placebo-subtracted proportion was 23-34%. NB32 was associated with a decrease in waist circumference, serum triglycerides and insulin resistance and an increase in high-density lipoprotein-cholesterol (HDL-C). Blood pressure mainly remained stable but there was a small increase in heart rate. The most common side effects were nausea, constipation, headache and vomiting. Serious adverse effects, which were very rare, included suicidal thoughts and seizures. In the majority of patients NB32 treatment was well tolerated.
Conclusions: Naltrexone/bupropion combination appears to be an effective adjunct to a comprehensive lifestyle intervention in order to achieve weight loss and treat obesity-related comorbidities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.14310/horm.2002.1600 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Excess Weight Loss at 6 Months Following Laparoscopic Sleeve Gastrectomy Correlates with the Remission of Hyperuricemia.
Obes Surg
January 2025
Center for Obesity and Hernia Surgery, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Background: Hyperuricemia is a metabolic disorder associated with obesity. Many studies have reported the effect of bariatric surgery on the decrease of serum uric acid level in patients with hyperuricemia. However, since the update of diagnostic criteria of hyperuricemia, the correlation between preoperative body mass index, postoperative weight changes, and the remission of hyperuricemia in patients with obesity after sleeve gastrectomy requires consensus.
View Article and Find Full Text PDFIdentifying specific subgroups of older patients at risk of repeated hospital readmissions and death after discharge in a prospective multicentre cohort in France.
BMJ Open
January 2025
Univ. Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, Lille, France.
Objective: To identify specific subgroups of older patients at risk of repeated hospital readmissions and death.
Design: Prospective, multicentre, DAMAGE (Patient Outcomes After Hospitalization in Acute Geriatric Unit) cohort of adults aged 75 and over, discharged from an acute geriatric unit (AGU) and followed up for 12 months.
Setting: Six recruiting hospital centres in the Hauts-de-France and Normandie regions of France.
Slimmer's paralysis in a physical trainer with drastic weight fluctuations.
BMJ Case Rep
January 2025
Orthopaedics, All India Institute of Medical Sciences, New Delhi, India.
Slimmer's paralysis is a peripheral mononeuropathy of the common peroneal (fibular) nerve (CPN/CFN), typically associated with rapid weight loss resulting in loss of subcutaneous fat pad and subsequent neural compression at the fibular head. Here, we describe a young man with a 1-year history of right-sided foot drop, which developed following a rapid intentional weight loss of 11 kg over a period of 15 days. This weight loss was preceded by rapid weight gain over 2 days owing to binge eating.
View Article and Find Full Text PDFIntermittent topical menthol treatment reduces white adipose tissue and leads to overweight loss in obese rats.
J Therm Biol
January 2025
Center for Natural and Humanities Sciences, Federal University of ABC (UFABC), São Bernardo Do Campo, SP, Brazil. Electronic address:
Obesity, recognized as a metabolic disease and a global epidemic, calls for novel pharmacological interventions. Menthol, an organic compound, has shown promise in increasing energy expenditure and has been proposed as a potential anti-obesity drug. While preclinical studies have demonstrated menthol's preventive effect on body mass gain, none have investigated its efficacy in treating obesity.
View Article and Find Full Text PDFPhytochemicals in Obesity Management: Mechanisms and Clinical Perspectives.
Curr Nutr Rep
January 2025
Research and Development cell, Department of Intellectual property Rights, Lovely Professional University, Jalandhar- Delhi Grand Trunk Rd., Phagwara, Punjab, 144411, India.
Purpose Of Review: This review explores the mechanistic pathways and clinical implications of phytochemicals in obesity management, addressing the global health crisis of obesity and the pressing need for effective, natural strategies to combat this epidemic.
Recent Findings: Phytochemicals demonstrate significant potential in obesity control through various molecular mechanisms. These include the modulation of adipogenesis, regulation of lipid metabolism, enhancement of energy expenditure, and suppression of appetite.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!